Skip to Main Content

The group of agents known as sedative-hypnotic drugs includes a variety of products used for the treatment of anxiety, depression, insomnia, and epilepsy. Besides common benzodiazepines, such as lorazepam, alprazolam, clonazepam, diazepam, oxazepam, chlordiazepoxide, and triazolam, this group includes the newer benzodiazepine-like hypnotics zolpidem, zopiclone, and zaleplon, and the muscle relaxants baclofen and carisoprodol. Ethanol and other selected agents are also popular recreational drugs. All of these drugs depress the central nervous system reticular activating system, cerebral cortex, and cerebellum.

CLINICAL FINDINGS

Mild intoxication produces euphoria, slurred speech, and ataxia. Ethanol intoxication may produce hypoglycemia, even at relatively low concentrations, in children and in fasting adults. With more severe intoxication, stupor, coma, and respiratory arrest may occur. Carisoprodol (Soma) commonly causes muscle jerking or myoclonus. Death or serious morbidity is usually the result of pulmonary aspiration of gastric contents. Bradycardia, hypotension, and hypothermia are common. Patients with massive intoxication may appear to be dead, with no reflex responses and even absent electroencephalographic activity. Diagnosis and assessment of severity of intoxication are usually based on clinical findings. Ethanol serum levels over 300 mg/dL (0.3 g/dL; 65 mmol/L) can produce coma in persons who are not using the drug long term, but regular users may remain awake at much higher levels.

TREATMENT

A. Emergency and Supportive Measures

Administer activated charcoal if the patient has ingested a massive dose and the airway is protected. Repeat-dose charcoal may enhance elimination of phenobarbital, but it has not been proved to improve clinical outcome. Hemodialysis may be necessary for patients with severe phenobarbital intoxication.

B. Specific Treatment

Flumazenil is a benzodiazepine receptor-specific antagonist; it has no effect on ethanol, barbiturates, or other sedative-hypnotic agents. If used, flumazenil is given slowly intravenously, 0.2 mg over 30–60 seconds, and repeated in 0.2–0.5 mg increments as needed up to a total dose of 3–5 mg. Caution: Flumazenil should rarely be used because it may induce seizures in patients with preexisting seizure disorder, benzodiazepine tolerance, or concomitant tricyclic antidepressant or other convulsant overdose. If seizures occur, diazepam and other benzodiazepine anticonvulsants will not be effective. As with naloxone, the duration of action of flumazenil is short (2–3 hours) and resedation may occur, requiring repeated doses.

+
Arens  AM  et al. Adverse effects from counterfeit alprazolam tablets. JAMA Intern Med. 2016 Oct 1;176(10):1554–5.
[PubMed: 27532131]
+
Penninga  EI  et al. Adverse events associated with flumazenil treatment for the management of suspected benzodiazepine intoxication—a systematic review with meta-analyses of randomised trials. Basic Clin Pharmacol Toxicol. 2016 Jan;118(1):37–44.
[PubMed: 26096314]
+
Vallersnes  OM  et al. Patients presenting with acute poisoning [ethanol, heroin, benzodiazepines, amphetamine, fire smoke, gamma-hydroxybutyrate and cannabis] to an outpatient emergency clinic: a one-year observational study in Oslo, Norway. BMC Emerg Med. 2015 Aug 13;15:18.
[PubMed: 26268351]

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.